Vanguard Capital Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$275K	Buy	+3,750	New	+$219K	0.32%	83

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Vanguard Capital Wealth Advisors's CRSP Position: Q2 2020 in Review

Vanguard Capital Wealth Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q2 2020: 3,750 shares worth $275K. The stake represents 0.32% of the portfolio and ranks #83 among its holdings.

276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

Vanguard Capital Wealth Advisors held 3,750 shares of CRISPR Therapeutics worth $275K as of Q2 2020.
CRISPR Therapeutics was a new Vanguard Capital Wealth Advisors position in Q2 2020.
CRISPR Therapeutics made up 0.32% of Vanguard Capital Wealth Advisors's portfolio in Q2 2020, its #83 holding.
276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.